Cost Effectiveness of Difelikefalin Compared to Standard Care for Treating Chronic Kidney Disease Associated Pruritus (CKD-aP) in People with Kidney Failure Receiving Haemodialysis.

ABSTRACT:

Background

Chronic kidney disease-associated pruritus (CKD-aP) is associated with an increased risk of depression, poor sleep and reduced health-related quality of life. Two phase III studies (KALM-1 and KALM-2) of difelikefalin showed reduced CKD-aP severity and improved itch-related health-related quality of life in patients with moderate and severe CKD-aP receiving haemodialysis for kidney failure.

Objective

We aimed to estimate the cost effectiveness of difelikefalin for patients with CKD-aP receiving haemodialysis for kidney failure compared to standard care from a UK National Health Service perspective.

Methods

A cohort model was developed with four health states representing levels of pruritus intensity over time, based on the KALM trials augmented with longer

SUBMITTER: Thokala P 

PROVIDER: S-EPMC10020261 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature